Merck Resubmits sBLA for KEYTRUDA with Extended Six-Week Dosing Schedule to Reduce Patient Contact During Pandemic

On April 23 local time, Merck & Co. announced that it had resubmitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) to update the dosing frequency of the anti-PD-1 therapy KEYTRUDA. The currently approved regimen is 200 mg every three weeks; the new submission proposes a 400 mg dose administered via intravenous infusion over more than 30 minutes every six weeks. The sBLAs cover all adult indications for KEYTRUDA, including both monotherapy and combination therapy.

KEYTRUDA is an anti-PD-1 therapy that works by enhancing the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes that may affect both tumor cells and healthy cells.

Roy Baynes, Vice President of Merck Research Laboratories, Global Head of Clinical Development, and Chief Medical Officer, stated, “During the COVID-19 pandemic, the oncology community rapidly adapted cancer care practices to minimize exposure and ensure that cancer patients were affected as little as possible. Accordingly, we developed a six-week dosing regimen for KEYTRUDA. We appreciate the FDA’s guidance during the resubmission process and look forward to continuing our close collaboration with the FDA.”

Reference Source:

Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule

Responsible Editor: Squirtle

Disclaimer: The views expressed in this article are solely those of the author and do not represent the position of Yaozhi.com. Readers are welcome to share and supplement their insights in the comments section. For reprints, please be sure to credit the author and source.